Genmab CEO: Preparing the company for the future
![Foto: Genmab/ PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article6255488.ece/ALTERNATES/schema-16_9/genmab-copenhagen-office.jpg)
Genmab’s chief executive is exhilarated as Medwatch catches him on the phone immediately following the disclosure of a targeted share issue to institutional investors - a share issue that has added DKK 998 million (USD 183 million) to the Danish biotech company’s capital base.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: The market overestimates Arzerra
For abonnenter
”It enables a whole new business model”
For abonnenter
Official: Genmab enters elite index
For abonnenter